SCHEMBL770187

SCHEMBL770187

Cc1ccccc1N1CCN(C(=O)CC(=O)N2CCC3CCCC=C3C2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.49
AR P10275 6/20 0.47
ADAMTS5 Q9UNA0 2/20 0.43
AKR1C3 P42330 1/20 0.43
HTR1A P08908 1/20 0.43
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
ALDH1A1 P00352 2/20 0.42
HTT P42858 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RBP4 P02753 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770214 0.94 AR (0.52) TSHRARADAMTS5AKR1C3ALDH1A1
SCHEMBL770433 0.92 AR (0.55) TSHRARADAMTS5AKR1C3ALDH1A1
SCHEMBL771347 0.92 AR (0.55) TSHRARADAMTS5AKR1C3ALDH1A1
SCHEMBL772030 0.88 TSHR (0.52) TSHRARAKR1C3ALDH1A1HTT
SCHEMBL769569 0.87 RAB9A (0.53) TSHRALDH1A1HTTMEN1KMT2A
SCHEMBL769758 0.82 TSHR (0.48) TSHRARADAMTS5AKR1C3ALDH1A1
SCHEMBL770894 0.82 KDM1A (0.39) ALDH1A1HTTKMT2AMAPTRBP4
SCHEMBL770075 0.81 ALDH1A1 (0.42) ALDH1A1MEN1KMT2A
SCHEMBL771534 0.81 L3MBTL1 (0.57) TSHRHTR1AALDH1A1MEN1KMT2A
SCHEMBL770397 0.80 ALDH1A1 (0.36) ALDH1A1HTTKMT2AMAPTRBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 TSHR 3844/4885AR 2000/4885ADAMTS5 515/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 TSHR 3858/4885AR 2012/4885ADAMTS5 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.